Ab­b­Vie los­es a round in the heavy­weight biosim­i­lar fight over Hu­mi­ra patents

Few drugs at­tract the kind of at­ten­tion from the biosim­i­lars crowd that Hu­mi­ra war­rants. Ab­b­Vie gets the li­on’s share of its rev­enue from this $16 bil­lion be­he­moth and the bio­phar­ma com­pa­ny has sworn to guard its patents with a le­gion of the best paid at­tor­neys in the field.

But the gener­ics crowd con­tin­ues to chip away at its IP foun­da­tion.

On Tues­day Co­herus Bio­Science scored a key win in its on­go­ing bat­tle to mar­ket a knock­off. The US Patent and Trade­mark Of­fice’s Patent Tri­al and Ap­peals Board ruled in its fa­vor on one of a set of patents, for ‘135, trig­ger­ing an 8% surge in its share price $CHRS and a 2.3% drop for Ab­b­Vie $AB­BV.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER